Podcasts about chief commercial

On this episode of This Week in Pharmacy, we spotlight two major conversations shaping the future of pharmacy practice in 2026. First, we welcome Dr. Lisa Faast, PharmD, founder of DiversifyRx, to discuss the Pharmacy Profit Summit 2026 and how independent pharmacies can strengthen margins, diversify revenue streams, and build sustainable growth models in today's reimbursement environment. Then, we turn to Rare Disease Day 2026 with Richard Ferris, PharmD, Chief Commercial & Clinical Officer at PantherRx, to discuss specialty pharmacy leadership, pharmacist impact, and new patient feedback data revealing communication gaps in rare disease care. Segment 1: Pharmacy Profit Summit 2026 Guest: Dr. Lisa Faast, PharmD | Founder, DiversifyRx Dr. Faast joins us to break down the vision behind Pharmacy Profit Summit 2026 — an event designed to equip pharmacy owners with practical strategies to increase profitability while maintaining clinical excellence. Key Topics Covered: • Why independent pharmacies must move beyond traditional dispensing revenue  • Diversification strategies including niche services and high-value offerings  • Real-world financial benchmarks pharmacy owners should track  • How mindset, leadership, and data discipline drive sustainable profitability  • The importance of collaboration and shared intelligence among pharmacy entrepreneurs The Pharmacy Profit Summit is not just about revenue — it's about equipping pharmacy owners to compete intelligently in a rapidly consolidating healthcare market. Segment 2: Rare Disease Day 2026 Guest: Richard Ferris, PharmD | PantherRx Rare Pharmacy In recognition of Rare Disease Day 2026, we are honored to welcome Richard Ferris, PharmD, to discuss the critical role pharmacists play in specialty pharmacy and rare disease care. PantherRx recently released survey findings examining patient and caregiver experiences within rare disease treatment journeys. Key Study Highlights: • 90% of patients and caregivers report delays due to communication gaps  • 68% report waiting for updates from providers, pharmacies, or insurers  • 90% say they manage the care process themselves  • 72% desire a dedicated care coordinator  • 73% agree it is unclear who is responsible for coordinating rare disease care Despite advances in specialty therapeutics, patients are still asking for the fundamentals: clear communication, coordinated care, and personalized support. Richard discusses: • The growing importance of specialty pharmacists as care coordinators  • Why rare disease patients often feel burdened by system fragmentation  • How specialty pharmacy can close communication gaps  • The need for pharmacist-led continuity in complex therapy management Rare Disease Day reminds us that specialty pharmacy is not only about high-cost medications — it is about human connection, long-term coordination, and advocacy for patients navigating some of the most complex clinical journeys in healthcare.  From business sustainability to patient-centered specialty care, this episode reinforces two realities: Pharmacy must remain financially strong to survive. Pharmacists must remain clinically present to lead. As the profession evolves, profitability and patient advocacy are not opposing forces — they are interdependent pillars of pharmacy's future. Listen now and join the conversation shaping Pharmacy in 2026.

Bob Mountain rejoins the domain industry with new role at D3. About one year after retiring from GoDaddy, Bob Mountain is back in the domain industry as the Chief Commercial and Revenue Officer for D3 Global. On today's show, Bob explains why he believes in D3's mission of marrying the DNS with blockchain technology. He […] Post link: Bob Mountain climbs the blockchain- DNW Podcast #573 © DomainNameWire.com 2025. This is copyrighted content. Domain Name Wire full-text RSS feeds are made available for personal use only, and may not be published on any site without permission. If you see this message on a website, contact editor (at) domainnamewire.com. Latest domain news at DNW.com: Domain Name Wire.

Unified commerce is everywhere — but Pim Vijftigschild (Chief Commercial & Partner Officer at New Black) argues the next wave is bigger: contextual commerce.In this episode, we break down what “contextual” actually means in retail: capturing the interaction that leads to the transaction, rebuilding the “black book” level of customer understanding, and why most enterprise retail architectures (and RFPs) are stuck in the past.We also get into why modern retail transformation is 15% technology and 85% courage, how retailers get trapped in Frankenstacks and “best-of-breed” RFP thinking, and why click & collect became the wake-up call for legacy systems.Plus: a look at New Black's NRF plans, including iOS Avenue (a live store experience built with an ecosystem of partners) and a world tour concept designed to help retailers bring NRF inspiration back home and translate vision into execution.What you'll learn:How to convert any interaction into a transactionWhy retail tech stacks must shift from an enterprise pyramid to a customer-first funnelThe hidden failure in best-of-breed RFPs (and what's missing)Why “open heart surgery” is the right metaphor for POS changeHow brand communities move from one-way “clienteling” to two-way belongingGuest: Pim Vijftigschild, Chief Commercial & Partner Officer, New BlackTopic: Contextual commerce, retail transformation, platform strategy, communities, NRF

Supply chains around the world are navigating relentless disruption, rising expectations for speed and resilience, and rapid advances in AI-driven decision-making. Leaders are under pressure to move beyond experimentation and deliver measurable value faster than ever.In this episode of Supply Chain Now, host Scott Luton sits down with two industry leaders: Philip Vervloesem, Chief Commercial & Markets Officer at OMP, and Scott Barnard, Managing Director at Bluecrux, live from the Gartner Supply Chain Planning Summit in Denver. Drawing on their work across global enterprises, both guests discuss how organizations translate advanced planning concepts into real-world results.The interviews with Philip and Scott explore the evolution toward autonomous, data-driven planning, the importance of self-funding ROI models, and why successful transformation depends on blending human expertise with machine intelligence. From OMP's Unison platform and rapid value delivery approach to Bluecrux's AI-powered analytics and decision intelligence capabilities, the conversation highlights how supply chain leaders can move from surface-level automation to profound, scalable impact.Jump into the conversation:(00:00) Intro(00:19) Gartner Supply Chain Planning Summit overview(01:15) Interview with Philip Vervloesem from OMP(02:05) OMP's approach to supply chain optimization(03:52) Challenges and innovations in supply chain(08:09) Interview with Scott Barnard from Bluecrux(09:03) Bluecrux's Solutions and Innovations(11:08) AI and supply chain balance(13:33) Upcoming eventsAdditional Links & Resources:Connect with Philip Vervloesem: https://www.linkedin.com/in/philipvervloesemConnect with Scott Barnard: https://www.linkedin.com/in/scott-barnard-a350814/Learn more about OMP: https://www.omp.comLearn more about Bluecrux: https://www.bluecrux.comLearn more about our hosts: https://supplychainnow.com/aboutLearn more about Supply Chain Now: https://supplychainnow.comWatch and listen to more Supply Chain Now episodes here: https://supplychainnow.com/program/supply-chain-nowSubscribe to Supply Chain Now on your favorite platform: https://supplychainnow.com/joinWork with us! Download Supply Chain Now's NEW Media Kit: https://bit.ly/3XH6OVkThis episode was hosted by Scott Luton and produced by Trisha Cordes, Joshua...

In this week's episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Elizabeth Jeffords, CEO, Iolyx Therapeutics, which is developing targeted therapies to address inflammation in ocular disease. Elizabeth is a seasoned biotech leader with experience spanning company building, fundraising, clinical development, major product launches and a >$9 billion global P&L. Before Iolyx, she served as Chief Commercial & Strategy Officer at Alkahest and held leadership roles at Genentech and Roche. An angel investor with Portfolia, she serves on several boards, including the boards of Iolyx, Ashvattha and Biotechnology Innovation Organization (BIO). Elizabeth holds a Bachelor of Science (BS) in Biology & Management from Yale and a Masters of Business & Technology from UNSW, Australia, which she attended as a Fulbright Scholar. Tune in to learn more about addressing inflammation in ocular diseases such as dry eye disease and more. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Today on the Pre-Hospital Care Podcast, we're diving into one of the most critical and often misunderstood areas of pre-hospital care: defibrillation and the future of cardiac arrest management. We're all familiar with the mantra of “shock early,” but how much of what we believe about defibrillation is grounded in evidence, and how much is myth carried forward through tradition and training?To help us separate fact from fiction, I'm joined by Michael Heller, Chief Commercial and Strategy Officer for Corpuls, a company at the forefront of resuscitation technology. Michael brings a unique perspective, not just from the engineering and innovation side, but also from working closely with clinicians worldwide to understand what truly makes a difference at the roadside.In this conversation, we'll explore the enduring myths of defibrillation, the technologies shaping the next generation of devices, and how data, AI, and post–cardiac arrest strategies could redefine survival over the next five years. This is about challenging assumptions, sharpening our practice, and looking ahead to what's possible in saving lives. You can find out more about Corpuls here: https://corpuls.world/en/

Let us know what's on your mindWe go inside Hockey Ireland's ten-week sprint to transform the Sport Ireland Campus into a Pro League venue with world-class broadcast, a sold-out crowd, and a free fan village that widens the sport's reach. Chief Commercial and Marketing Officer Nick McElwee brings us inside the decision-making process that will deliver World Class Hockey in Dublin this week.• Winning hosting rights on a ten-week timeline• Leaning on a small core team and expert partners• Turning a campus into a functioning venue• Balancing weather risk, branding, and broadcast needs• Building a world-feed TV product with 10 cameras• Funding mix, de-risking, and early ticket sales• Creating FOMO with a 1,500-seat sell-out• Opening a free fan village to grow visibility• Using experience from Formula One-scale events Find out more about what we do day in day out at Sportforbusiness.comWe publish a daily news bulletin and host regular live events on a wide range of sporting subjects. Subscribe to the podcast wherever you get your podcasts from, and look forward to more upcoming chats on leadership and the business of sport.Our upcoming live events on Women in Sport and the Sporting Year Ahead, as well as plenty more, are live on the Sport for Business website, and we'd love to have you join us.

What does it take to modernize a legacy sport, inspire global fans, and build commercial engines that stand the test of time?In this episode, Linnea Jungnelius sits down with Jeff Price, Chief Commercial & Philanthropy Officer at the PGA of America, and one of the most influential architects behind golf's modern growth story.From transforming brand partnerships at Gatorade and MasterCard to reshaping how millions experience the PGA Championship and Ryder Cup, Jeff has built a career at the intersection of sport, business, and innovation. His lessons apply far beyond the fairway: they're about building trust, culture, and commercial momentum in any business facing disruption.What You'll Learn:• How to turn sponsorships into lasting, growth-driving partnerships• The leadership shift from instructing teams to empowering them• Why understanding your “dual-habit” consumers drives sustainable engagement• How to extend experiences beyond the venue and into culture• Why focus and the smart use of AI defines the next wave of sports innovationTimecodes:00:00 Intro00:26 Guest Introduction: Jeff Price1:09 Early Career & Lessons from Rejection 02:45 Career Journey: NBA, Gatorade, MasterCard06:31 Startup Experience & Learning from Failure08:43 Leadership Evolution: Empowerment vs. Instruction10:16 Decision-Making & Strategic Frameworks11:37 Joining PGA of America: Strategic Gaps & First Moves13:15 Partnership Economics & PGA's Commercial Strategy17:10 Ryder Cup: Brand Unification & Global Growth20:36 Commercial Innovation: Events, Experiences, and Media22:51 Media Strategy: ESPN+ Streaming Deal25:42 The Future: AI, Data, and Personalization in Golf30:05 Building High-Performing Teams: The “We” Mentality32:51 Commercial Leadership: Data, Social Media, and Revenue34:01 Advice for CEOs & Commercial Teams35:00 Personal Routines & Sustaining Performance36:41 Sources of Inspiration & Industry Trends38:01 Trends in Sports Business & Media49:00 Lightning Round: Personal ReflectionsResources: Jeff Price: LinkedIn: ⁠https://www.linkedin.com/in/jeff-price-24481318/Linnea Jungnelius: LinkedIn: https://⁠www.linkedin.com/in/linneajungnelius ⁠X: ⁠https://x.com/itslinnea⁠ Explore the Podcast: Spotify: ⁠https://acertitu.de/jeff-price-spotify-podcast Apple Podcasts: ⁠https://acertitu.de/jeff-price-apple-podcast⁠Blog: ⁠https://acertitu.de/jeff-price-blog⁠ Found Value?

Episode 125 | DP & McGheeDavid and Tim return from the long weekend ready to dive into a packed episode filled with college football, NASCAR drama, and Ryder Cup anticipation. From major wins on the field to intense battles off of it, this episode covers the latest developments across multiple sports while featuring two powerhouse guests from the world of golf.Here's what they cover:

Alejandra Gauna (CCO, Chief Commercial Oficcer de labs357) Unas Cuantas Verdades @marianoobarrio

In this episode, we welcome back Michael to explore Vertical's progress with its VX4 eVTOL aircraft and ambitious roadmap toward certification and commercial operations by 2028. Michael shares a behind-the-scenes look at how the VX4 prototype has been exceeding expectations in recent flight tests, showcasing exceptional stability, efficiency, and ultra-low noise performance. He dives into the technical and strategic decisions shaping the final aircraft design, from battery safety innovations to partnering with the UK CAA and EASA for high-standard certification. Listeners will gain insights into the meticulous engineering, operational learnings, and regulatory engagement that are de-risking Vertical's journey to market. Michael also reflects on Vertical's newly signed partnership with Bristow, a move that will enable scalable commercial operations through wet lease models—especially for airport shuttle services.

During the last few episodes, we’ve been discussing the benefits of a good hiring team in developing job specs as a foundation for recruiting, evaluating, and selecting successful managers and executives. I was recently asked to do an executive assessment for a media company that (in part) provides information to businesses to help them protect assets and people’s lives, minimize costs, and maximize sales opportunities. It’s been a successful segment that needs acceleration, The position is Senior Vice President. Business Intelligence, a B to B program development and execution role. In prior years, Business Intelligence had its own sales, marketing, technical, and operations groups reporting to a profit center GM. Now these groups are under separate functional leaders in a new matrix environment. So, the only people directly managed by the SVP are project managers and an inside service and sales support team. The job specs focused on the SVP’s needs to be a great collaborator in both program development and implementation. Initially, I’m thinking that collaborative team play is a key element along with strong program analytic, development, organization, and coordination skills. However, the hiring team’s job description used words like “spearhead and drive the business” which sounded more like direct business leadership. The CEO helped me get clearer the organization structure change and the matrix emphasis. The candidate’s background emphasized organizational and executive support but not direct business driving positions. That said, there was noteworthy success in business analytics related to mergers and acquisitions and playing a support role in orchestrating these organizational growth deals. In the most recent job, he had some influence in getting his company to create a separate business division of a previously integrated enterprise. He was appointed to a Chief Commercial job where he supported the Sales VP in shaping and negotiating sales contracts at the executive level. The candidate also had nice experience in SaaS companies, a similar to my client. Watch https://youtu.be/gOnzkSmSUMg

During the last few episodes, we’ve been discussing the benefits of a good hiring team in developing job specs as a foundation for recruiting, evaluating, and selecting successful managers and executives. I was recently asked to do an executive assessment for a media company that (in part) provides information to businesses to help them protect assets and people’s lives, minimize costs, and maximize sales opportunities. It’s been a successful segment that needs acceleration, The position is Senior Vice President. Business Intelligence, a B to B program development and execution role. In prior years, Business Intelligence had its own sales, marketing, technical, and operations groups reporting to a profit center GM. Now these groups are under separate functional leaders in a new matrix environment. So, the only people directly managed by the SVP are project managers and an inside service and sales support team. The job specs focused on the SVP’s needs to be a great collaborator in both program development and implementation. Initially, I’m thinking that collaborative team play is a key element along with strong program analytic, development, organization, and coordination skills. However, the hiring team’s job description used words like “spearhead and drive the business” which sounded more like direct business leadership. The CEO helped me get clearer the organization structure change and the matrix emphasis. The candidate’s background emphasized organizational and executive support but not direct business driving positions. That said, there was noteworthy success in business analytics related to mergers and acquisitions and playing a support role in orchestrating these organizational growth deals. In the most recent job, he had some influence in getting his company to create a separate business division of a previously integrated enterprise. He was appointed to a Chief Commercial job where he supported the Sales VP in shaping and negotiating sales contracts at the executive level. The candidate also had nice experience in SaaS companies, a similar to my client. Watch https://youtu.be/gOnzkSmSUMg

During the last few episodes, we've been discussing the benefits of a good hiring team in developing job specs as a foundation for recruiting, evaluating, and selecting successful managers and executives.  I was recently asked to do an executive assessment for a media company that (in part) provides information to businesses to help them protect assets and people's lives, minimize costs, and maximize sales opportunities. It's been a successful segment that needs acceleration, The position is Senior Vice President. Business Intelligence, a B to B program development and execution role.  In prior years, Business Intelligence had its own sales, marketing, technical, and operations groups reporting to a profit center GM. Now these groups are under separate functional leaders in a new matrix environment. So, the only people directly managed by the SVP are project managers and an inside service and sales support team. The job specs focused on the SVP's needs to be a great collaborator in both program development and implementation. Initially, I'm thinking that collaborative team play is a key element along with strong program analytic, development, organization, and coordination skills. However, the hiring team's job description used words like “spearhead and drive the business” which sounded more like direct business leadership. The CEO helped me get clearer the organization structure change and the matrix emphasis. The candidate's background emphasized organizational and executive support but not direct business driving positions. That said, there was noteworthy success in business analytics related to mergers and acquisitions and playing a support role in orchestrating these organizational growth deals. In the most recent job, he had some influence in getting his company to create a separate business division of a previously integrated enterprise. He was appointed to a Chief Commercial job where he supported the Sales VP in shaping and negotiating sales contracts at the executive level. The candidate also had nice experience in SaaS companies, a similar to my client. Watch https://youtu.be/gOnzkSmSUMg

Helsedata har et enormt potensial til å fremme både folkehelsen og innovasjon i helsesektoren. Likevel står vi overfor store utfordringer knyttet til deling og bruk av disse dataene. Hva hindrer fremdriften? Hvem drar nytte av tilgjengelige data, og hvordan kan vi bruke dem til å skape et mer bærekraftig og fremtidsrettet helsevesen?Lytt til samtalen mellom:Sharmini Alagaratnam, Director, Healthcare research, DNV og Styreleder, PF HelseAslak Hougen, Chief Commercial officer, Ambr InstituteSteinar Thoresen, MD, NordicRWEJoachim Thorkildsen, assisterende fagdirektør, Avdeling for medisin og helsefag, Vestre Viken HF Benedikte Thunes Akre, Styremedlem, Oslo Cancer Cluster, Head of Oncology Medical: Nordics/CEEBA/WESE, AstraZeneca og styremedlem, PF HelseI denne episoden lærer du om hvorfor god bruk av helsedata er viktig. Om det historiske rundt det å bruke helsedata i blant annet legemiddelutvikling. Om hvordan det er å få tak i helsedata raskt nok i dag og hvilke utfordringer forskerne møter på i møte med jussen og myndighetene. Til slutt får du panelets anbefalinger til hvordan vi kan sikre god bruk av helsedata – for å skape et mer bærekraftig og fremtidsrettet helsevesen. Hosted on Acast. See acast.com/privacy for more information.

Paul Archer is the Chief Commercial Strategy Officer at Envision Pharma Group and a seasoned commercial strategist with more than 20 years of experience transforming pharma communications and driving revenue growth. With a strong background in healthcare communications and a flair for innovative service development, Paul has consistently guided companies to embrace integrated, data-driven commercial strategies that bridge scientific excellence with tangible market impact.In this episode, host Matt Milligan and Paul dive into building scalable commercial strategies for today's ever-evolving pharma landscape. They explore how digital innovations, cost optimisation, and behavioral insights can fuel success amid industry shifts. Paul shares his firsthand experiences in overcoming market cycles, merging operational efficiency with strategic growth investments, and aligning commercial strategy with real-time market data. His clear vision and hands-on approach position him as a transformative leader in both commercial strategy and pharma sales.00:00 – Introduction & Theme00:01:10 – Paul Archer's Background & Early Career Insights00:02:30 – Evolving Commercial Strategy in Pharma00:03:15 – Transforming Client Engagement and Market Cycles00:04:00 – Leveraging Digital Innovation & AI in Pharma Marketing00:05:00 – Integrating Cost-Cutting with Growth Strategies00:06:15 – Building Resilient Commercial Teams through Data-Driven Coaching00:07:00 – Aligning Sales Strategy with Real-Time Market Data00:08:15 – Managing Change for Enhanced Productivity00:09:00 – Final Thoughts & Contact

Nosipho Radebe speaks to Jay Govender, Chief Commercial and Legal Officer at Etana EnergySee omnystudio.com/listener for privacy information.

In this episode, Erica Brinker, Chief Commercial and Sustainability Officer at Chaberton Energy and board member of the Coalition for Community Solar Access, shares her unique career journey and insights into the renewable energy sector. The conversation covers:Erica's early roles in the fashion and luxury goods industry, followed by her transition to healthcare technology, aerospace, and eventually renewable energy, reflecting her customer-centric approach throughout.Navigating the challenges in renewable energy including the complexities of stakeholder engagement, from landowners to policymakers, and the importance of understanding diverse priorities to drive successful projects.How Chaberton prioritizes markets, balances risks, and integrates policy insights to develop high-quality solar solutions tailored to different stakeholder needs.Erica's work with the Coalition for Community Solar Access and reflections on how industry collaboration drives impactful policy changes at state and federal levels.Check out Chaberton Energy at https://www.chaberton.com/.Tune in now for an insightful conversation about shaping the future of clean energy!Paces helps developers find and evaluate the sites most suitable for renewable development. Interested in a call with James, CEO @ Paces?

What does it take to transition from aerospace to leading the nation's #1 fastest-growing community solar developer? In this episode, Catherine McLean spoke with Erica Brinker, Chief Commercial & Sustainability Officer at Chaberton Energy, about the company's 7,300% growth & its origination of 350 MW annually. Some of the company's recent work includes floating solar projects with Noria Energy & community solar projects throughout the U.S. with Pivot Energy & Prosperity Works. Erica also shared about how Chaberton is donating $5,000 per MW deployed to local communities, prioritizing pollinator habitats, & about some of toughest decisions she's had to make in her role at Chaberton. If you're a clean energy employer & need help scaling your workforce efficiently with top tier staff, contact Catherine McLean, CEO & Founder of Dylan Green, directly on LinkedIn: https://bit.ly/3odzxQr. If you're looking for your next role in clean energy, take a look at our industry-leading clients' latest job openings: bit.ly/dg_jobs. 

Kasper Sierslev, Chief Commercial and Creative Officer at ZITE, delves into elevating in-house marketing. Companies are bringing roles like graphic designers and copywriters in-house, but for these in-house teams to succeed, they must lay the necessary groundwork. From hiring project managers with industry knowledge to collaborating with external agencies, companies can empower their in-house teams for success. Today, Kasper discusses maximizing in-house marketing competencies.Connect With: Kasper Sierslev: Website // LinkedIn // TwitterThe Rebrand Podcast: Email // LinkedIn // TwitterI Hear Everything: IHearEverything.com // LinkedInSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Kasper Sierslev, Chief Commercial and Creative Officer at ZITE, delves into elevating in-house marketing. Traditionally considered the place where creativity goes to die, in-house marketing is undergoing a profound transformation. With companies bringing more creative talent in-house and leveraging AI tools, the lines are blurring between content, tier two, and production. Today, Kasper discusses revolutionizing in-house marketing.Connect With: Kasper Sierslev: Website // LinkedIn // TwitterThe Rebrand Podcast: Email // LinkedIn // TwitterI Hear Everything: IHearEverything.com // LinkedInSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Joey Raheb is Chief Commercial & Broking Officer for Aon Health Solutions. In this week's episode he connect with co-host Mark Edgar to discuss the future of total rewards.They discuss how AI will impact total rewards and the changing expectations of employees.You can connect with Joey here!Join our communityIf you're interested in being part of these conversations, consider joining our foHRsight+ community. You can learn more here.Quick reminderDon't forget to sign up for our weekly newsletter foHRsight at www.futurefoHRward.com/subscribe.Follow us on LinkedIn:Mark - www.linkedin.com/in/markedgarhr/ Naomi - www.linkedin.com/in/naomititlemancolla/future foHRward - www.linkedin.com/company/future-fohrward/ And on Instagram - www.instagram.com/futurefohrward/foHRsight+ is a private digitally-powered community for forward thinking senior HR leaders committed to making work better. Click here to express interest in joining– we are welcoming new members in our Fall CHRO and VP+ HRBP & Talent cohorts until November 15th! Support the show

In today's episode of Clicks2Bricks, we are joined by Ash ElDifrawi in his capacity as the Chief Commercial and Brand Officer for The Aspen Group (TAG), a portfolio of health-services brands. Ash is here to talk about the unique challenges of growing and supporting a national dentistry brand, and he is perfectly situated as two of the brands under TAG's umbrella are the only two national dentistry brands in the country! We learn about Ash's father and son podcast, Hold Me Back, before dissecting the inner workings of TAG as a company. We discuss how TAG's daughter companies are structured, how to overcome the challenges of the modern marketing funnel, the marketing relationship between TAG and its affiliated dental practitioners, and why the company relies so heavily on influencers and social media in its marketing efforts. Ash also explains the roles of customer reviews and AI at TAG, why he believes that marketing should be redefined in line with our evolving world, and how his experience at previous companies serves him in the work he does today, as well as the job opportunities that are currently available at The Aspen Group. Tune in for all this and more!Key Points From This Episode:Insight into Ash's father-son podcast, Hold Me Back.The ins and outs of Aspen Dental and The Aspen Group (TAG). Exploring Ash's journey at TAG and how his role has changed through various titles.A closer look at all the brands under the TAG umbrella and how they're structured. TAG's marketing funnel and the unique challenges that come with it. The thrills and spills of managing the only two national brands in dentistry. How TAG engages with its network of dental practitioners from a marketing perspective.Filling the funnel: understanding what works in today's market. How (and why) TAG uses influencers and social media marketing. Why Ash and his team are more focused on the first visit than retaining customers.Customer reviews and the role of AI at TAG. Ash's unpopular opinion about the evolution of the definition of marketing!How previous experiences at Google, GoGo, and Redbox influence the way he works today. The differences between general cognitive ability, talent, education, and experience. Job vacancies at TAG and how to connect with Ash and his team.Links Mentioned in Today's Episode:Ash ElDifrawi on LinkedInAsh ElDifrawi Books on AmazonThe Aspen Group (TAG)Hold Me Back PodcastAI Xecutive CouncilBob Fontana on LinkedIn RedboxGogo Business AviationRaising Cane'sMarriot International Warby ParkerSOCiClicks 2 Bricks Marketing Leaders Coffee Chat

On today's episode, we catch up with Oana Jinga, co-founder, Chief Commercial and Product Officer for Dexory to learn all about the Dexory warehouse inventory management solution. Also on this episode, we feature a conversation between editorial director Gene Demaitre and Garret Place, Business Development for robotic perception at ifm.

In this episode, Blythe and Oana Jinga, Co-Founder and Chief Commercial and Product Officer at Dexory, discuss the company's tall, autonomous robotics solution that collects granular data from warehouses to create a dynamic digital twin environment. Jinga shares insights on leveraging this data for optimization, consolidating product locations, identifying discrepancies with WMS systems, and orchestrating other robotics operations.LINKS:Oana's LinkedInDexory's WebsiteQUOTES:"The way we look at a digital twin is like it's a dynamic and living and breathing digital object. So it needs to be able to show you at any point in time, what's the latest that's happening in the physical world [of your warehouse], how that's evolving, and what factors are influencing that change." - Oana Jinga "The robot is there to collect information. But what you can do with that information, is pretty much limitless. You can extract data and different points, you can compare it with other data sources, you can crunch it, you can use it for simulation for forecasting, and so on." - Oana Jinga "So when we say a digital twin of a warehouse, we literally mean like this digital environment that changes continuously as the warehouse changes, and that you can also then use in the future, like if you do want to simulate and try different scenarios." - Oana Jinga "From our perspective, we use the robot to get data continuously from warehouses to push them into that digital twin and show as close to reality as possible what's going on." - Oana Jinga "We take continuous pictures of the racks, and then we deconstruct those and can use computer vision. And again, some elements of machine learning to see what we're seeing in that data." - Oana JingaWATCH THE FULL EPISODE HEREFeedback? Ideas for a future episode? Shoot us a text here to let us know.---------------------------------------------THANK YOU TO OUR SPONSORS!Are you experienced in freight sales or already an independent freight agent? Listen to our Freight Agent Trenches interview series powered by SPI Logistics to hear directly from the company's agents on how they took the leap and found a home with SPI freight agent program. Tai TMS is designed to streamline your brokerage operations and propel growth for both FTL and LTL shipment cycles. Book a demo with the Tai team today and tell them Everything is Logistics sent you. Maximize your website's performance as a sales tool with Digital Dispatch's website management.

Episode 063 – Steven Malony, CEO, Belkin On this episode of the Executives' Exchange we are honored to be joined by a versatile role model who broadened his mindset abroad, Steven Malony, CEO of Belkin. He is known for his many different roles and international experience which make him a strong and well-rounded business executive. Hear how a new perspective can really help strengthen and form a leader. This episode was recorded in front of a live audience on October 3, 2023.   00:00 – Intro 0:57 – Steven's personal background 2:53 – How he got into Sales 5:06 – Career timeline 6:38 – Advice for international assignments 8:22 – Which experience best prepared you for your role as CEO? 9:38 – Transition to CEO 12:23 – Company rebranding 14:16 – What is next for technology? 15:53 – How to know what technology to invest in next? 18:01 – How Falcon decided to go into audio products 20:49 – Managing working with competitors 22:40 – Word from our sponsor, Shure 23:32 – How COVID-19 affected business strategies 29:42 – Energy efficiency and sustainability 36:18 – Advice for CEOs 40:40 – How he prioritizes company initiatives 42:00 – His favorite product 43:00 – Outro   Episode Link: Belkin   Guest Host: Chris Corley, Chief Commercial and Operating Officer, CDW Producer: Eva Penar, Chief Content & Communications Officer, The Executives' Club of Chicago      Subscribe on Apple, Spotify, or wherever you listen to podcasts.    Thank you to our podcast sponsor, Shure Incorporated.   For nearly 100 years, Shure Incorporated has developed best-in-class audio products that provide high-quality performance, reliability and value. Headquartered in Niles, Illinois, our history of innovation and expertise in acoustics, wireless technology, and more enables us to deliver seamless, transparent audio experiences to a global audience. Our diverse product line includes world-class wired and wireless microphones, networked audio systems and signal processors, conferencing and discussion systems, software, a loudspeaker, and award-winning earphones and headphones.   Find Shure on: Facebook | LinkedIn | Instagram

“Entrepreneurship feels like a process of torture sometimes because no matter how hard you try and how much you work and how many evenings or weekends that you sacrifice, you're still only at the very bottom of the hill.”  Today's 40 Minute Mentor is Deirdre O'Neill, Co-Founder and Chief Commercial & Legal Officer at women's health startup, Hertility.  With a background in corporate law and VC law, Deirdre took the leap into entrepreneurship in 2019, alongside twin sister Dr Helen O'Neill and Dr Natalie Getreu.  Since then, the three Co-Founders and their team have been revolutionising the future of reproductive healthcare, by pioneering unique diagnostic testing.  In this episode, we get a full behind-the-scenes look into their build so far and where the future might take them…  Episode chapters:  ➡️ Growing up in Cork [07:30]  ➡️ Why she feels more like a lawyer now than ever before [10:33]  ➡️ Hertility's origin story [13:14]  ➡️ Breaking into a heavily regulated space [18:30]  ➡️ Normalising talking about fertility & women's health [20:27]  ➡️ Fundraising & why crowdfunding is a great option [23:11]  ➡️ Leaning into pregnancy as a Founder [29:05]  ➡️ Why the best talent is focusing on purpose [31:52]  ➡️ Are you choosing a steamboat or a speedboat? [33:15]  ➡️ Hertility's team culture [35:23]  ➡️ Audience Question: How do you navigate conflict with your Co-Founder and twin sister [40:13]  ⛳ Helpful links: ➡️ Connect with Deirdre: https://www.linkedin.com/in/deirdre-o-neill-a8bb6a14/  ➡️ Check out Hertility: https://hertilityhealth.com/  ⭐Enjoyed this episode?⭐️ Keep up to date with all our latest episodes, by hitting the subscribe button on your favourite podcast platform. And for any feedback on what you enjoy the most and ideas on what we can do to make 40 Minute Mentor even better, please leave us a review on https://ratethispodcast.com/40mm  Learn more about your ad choices. Visit megaphone.fm/adchoices

William A. Lumpkin (Will) is a devoted husband to Layla, a proud father to Ailey, Sage, and Liam, and a purpose-driven leader with a passion for delivering significant impact through high-performing teams. Will serves as Vice President of Sales at Agios Pharmaceuticals in Cambridge, MA, where he leads a team dedicated to providing disease education and access to first and best-in-class solutions for underserved patient populations affected by chronic hemolytic anemia. Prior to Agios, William was Head of New Product Strategy and Business Development at Alexion Pharmaceuticals, Chief of Staff to the Chief Commercial and Global Operations Officer, and the Commercial Integration lead for Alexion into Astra Zeneca rare disease. His innovative solutions earned him Guiding Star and Excellence Awards. With a diverse background spanning leadership across functional disciplines, including finance, sales, marketing, and strategy, at Baxter, Baxalta, Shire, and Takeda, Will has demonstrated his ability to build and lead teams that operate with a sense of urgency in service of others. His professional journey began in finance at Procter & Gamble and includes time as a lecturer at UNC Kenan Flagler School of Business. Will holds an MBA from the University of Chicago Booth School of Business and a Bachelor of Science in Finance from Indiana University, where he excelled as a four-time letterman, senior captain of the Hoosier football team, and President of the Alpha Chapter, Kappa Alpha Psi Fraternity, Inc. Originally from Dayton, Ohio, Will and his family reside in Houston, where he remains actively engaged in community leadership roles, including serving on the Hermann Park Conservatory Board and as a Senior Fellow at the American Leadership Forum. What you'll learn on this episode:  The power of purpose-driven leadership The impact of values on team building and work focus How to connect individual impact to organizational goals The significant role of communication and active listening Strategies for continuous leadership development and growth The importance of authenticity, honesty, and integrity in leadership Additional Resources: William's LinkedIn  Agios Pharmaceuticals' Website >> https://agios.com/  Learn more about PK Deficiency >>  https://www.knowpkdeficiency.com/ Learn more about opportunities to work with Agios and search their open positions below: https://phe.tbe.taleo.net/phe03/ats/careers/v2/searchResults?org=AGIOS&cws=37 

Welcome to another episode of The Brand Called You, where we explore the journeys of accomplished professionals from around the world. Today, we are excited to dive into the world of creative excellence with Kasper Sierslev, the Chief Commercial and Creative Officer of Zite. With a background rooted in traditional advertising, Kasper has emerged as a trailblazer in the realm of in-house creative teams. Join us as we uncover Kasper's insights and strategies for driving innovation and building high-performing in-house teams that redefine the boundaries of creativity. [00:33] - About Kasper Sierslev Kasper is the Chief Commercial and Creative Officer of Zite. He is also an author of two books. --- Support this podcast: https://podcasters.spotify.com/pod/show/tbcy/support

Karina Kogan is an award winning marketing and technology executive with a track record of feuling transformational growth and digital innovation for disruptor brands. Karina currently serves as Chief Commercial and Marketing Officer at Pvolve, an omnichannel fitness company that in 2023 announced a strategic partnership with Jennifer Aniston. Karina has spent two decades working at the intersections of innovation and marketing with prior roles as CMO of Oura, SVP & Global Head of Product Marketing at Peloton, and SVP of Digital Media and Products at WarnerMedia. Karina also holds board and advisory posts at Jackpot.com, FightCamp, among others. In This Conversation We Discuss:[00:46] Intro[02:19] Growing an omnichannel fitness brand[03:02] Reflecting on career journey to Pvolve[04:25] Jennifer Aniston's organic connection to Pvolve[06:28] Authenticity in brand-talent partnerships[07:21] Trend: celebrity collaborations in consumer brands[10:22] Electric Eye: your true Shopify experts[11:20] How functional fitness became the solution[12:59] Building strength and flexibility using Pvolve[13:49] Bringing on key team members to drive growth[14:54] Collaborating with agencies and vendors[15:42] Combining home workouts and in-person studios[16:43] The diverse responsibilities of a CMO[18:15] Stay relevant: the value of continuous learning[19:36] Strategic resource allocation for maximum ROI[20:41] Leveraging networking & relationships as startups[22:02] Tap into functional fitness with PvolveResources:Subscribe to Honest Ecommerce on YoutubeFunctional and omnichannel fitness with resistance equipment pvolve.com/Follow Karina Kogan linkedin.com/in/kogankarina/Schedule an intro call with one of our experts electriceye.io/connectIf you're enjoying the show, we'd love it if you left Honest Ecommerce a review on Apple Podcasts. It makes a huge impact on the success of the podcast, and we love reading every one of your reviews!

Kasper Sierslev, Chief Commercial and Creative Officer at ZITE, delves into elevating in-house marketing. Companies are bringing roles like graphic designers and copywriters in-house, but for these in-house teams to succeed, they must lay the necessary groundwork. From hiring project managers with industry knowledge to collaborating with external agencies, companies can empower their in-house teams for success. Today, Kasper discusses maximizing in-house marketing competencies.Connect With: Kasper Sierslev: Website // LinkedIn // TwitterThe Rebrand Podcast: Email // LinkedIn // TwitterI Hear Everything: IHearEverything.com // LinkedInSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Kasper Sierslev, Chief Commercial and Creative Officer at ZITE, delves into elevating in-house marketing. Traditionally considered the place where creativity goes to die, in-house marketing is undergoing a profound transformation. With companies bringing more creative talent in-house and leveraging AI tools, the lines are blurring between content, tier two, and production. Today, Kasper discusses revolutionizing in-house marketing.Connect With: Kasper Sierslev: Website // LinkedIn // TwitterThe Rebrand Podcast: Email // LinkedIn // TwitterI Hear Everything: IHearEverything.com // LinkedInSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In seinem heutigen Podcast diskutiert Erik mit Carsten Schwecke, Vorsitzender der Geschäftsführung der Seven.One Media und Matthias Dang, CCTDO von RTL Deutschland, über “Datafication of TV” und mit welchem Technologieansatz sie gemeinsam die Effizienz von Werbung steigern sowie Barrieren zwischen “digital” und “linear” abschaffen wollen. Im Einzelnen geht es um folgende Aspekte: - Werbekunden Dilemma: Erreiche ich im TV überhaupt noch meine Zielgruppe (in gewünschter Intensität und Wirkung)? - Welche Idee steckt hinter eurem gemeinsamen Ansatz “Datafication of TV”? - Wie wird die Erfolgsmessung in eure programmatischen Pläne mit eingebaut? - Wie bewertet ihr den Markteintritt von Amazon Prime Ads mit deren programmatischen Ansätzen und hoher Customer Base? - Wer sind heute und perspektivisch die schlauesten Advertiser? Carsten Schwecke (47) ist seit Oktober 2023 Vorsitzender der Geschäftsführung der Seven.One Media. In dieser Position verantwortet der Digital-Experte alle Werbevermarktungsbereiche bei ProSiebenSat.1 sowie die Weiterentwicklung der Werbeangebote, insbesondere in den Bereichen Joyn und innovative Werbeformen wie Advanced TV (Connected TV, Addressable TV und Programmatic TV). Seine berufliche Laufbahn begann der Diplom-Kaufmann 2002 in der Verlagsgruppe Handelsblatt. Nach weiteren Führungspositionen war Schwecke CEO des Axel-Springer-Vermarkters Media Impact und zuletzt CEO der Axel Springer All Media, wo er maßgeblich die digitale Transformation und Entwicklung neuer digitaler Geschäftsfelder vorantrieb. Matthias Dang ist Chief Commercial, Technology & Data Officer (CCTDO) von RTL Deutschland. In dieser Funktion führt er alle kommerziellen, technologischen und digitalen Aktivitäten des Unternehmens. Gleichzeitig ist er CEO des Vermarkters Ad Alliance. Von September 2021 bis Dezember 2023 war Matthias Dang Co-CEO von RTL Deutschland und zuvor drei Jahre als Geschäftsführer für die Bereiche Vermarktung, Technologie & Daten verantwortlich. Der Medienmanager verantwortet bereits seit 2012 die Geschäftsführung des RTL-Vermarkters, zunächst als Geschäftsführer IP Deutschland, dann als CEO der Ad Alliance.

Are you ready to be inspired by an accomplished and versatile marketing professional?Join us on the Conquer Local Podcast as we welcome Kasper Sierslev, Chief Commercial and Creative Officer at Zite. With a remarkable career, including collaborations with global giants like Apple, Lego, and Mars, Kasper's expertise in building and guiding in-house creative departments is unparalleled.An award-winning marketer and author of two best-selling books, 'Moving In-House' and 'Win-Win-House,' Kasper offers deep insights into in-house marketing dynamics that will leave you with a fresh perspective.Get ready to be captivated by his expertise and remarkable adaptability in diverse business landscapes!Giveaway Alert! Conquer Local Podcast listeners, grab your free copy of Kasper's 'Win-Win-House' book at www.win-win-house.com/vendastaConquer Local is presented by Vendasta. We have proudly served 5.5+ million local businesses through 60,000+ channel partners, agencies, and enterprise-level organizations. Learn more about Vendasta, and we can help your organization or learn more about Vendasta's Affiliate Program and how our listeners (like yourself) make up to $10,000 off referrals.Are you an entrepreneur, salesperson, or marketer? Then, keep the learning going in the Conquer Local Academy.

In this weeks episode of Let's talk “a little” loyalty Tom reviews the original podcast where Paula was joined by Javier Marin Martinon, Chief Commercial, Loyalty, and Customer Officer, who shares what Renfe, Spains leading railway company, have implemented for members of its loyalty program.   Railway travel may appear to be a strange environment for loyalty, but Javier explains how loyalty must be seen in terms of the journey, with the competition against plane and car travel, rather than with the destination.   Listen in for tips on how to engage the customer and create loyalty in a difficult sector, where the choices are limited by supply and the benefits are intangible. Hosted by Tom Peace. Show Notes: 1) ⁠Javier Marin Martinon⁠ 2) ⁠⁠⁠⁠Renfe⁠ 3) #254: Loyalty Innovation in the Railway Industry

Kyle hops on the podcast with Michael Hughes, Chief Commercial and Revenue Officer at ChargePoint, to discuss the latest news at the company regarding their NACS retrofit plans! Kyle and Michael go into detail about the NACS connector support for both AC and DC solutions that ChargePoint is now rolling out, the future of NACS at the company, how they plan to work with site hosts to decide the best next step for them and their needs, plus more technical and big picture details surrounding this news.ChargePoint Press Release: https://www.chargepoint.com/about/news/chargepoint-ramps-production-tesla-compatible-nacs-ev-chargersFind us on all of these places:YouTube: https://www.youtube.com/outofspecpodcastApple Podcasts: https://podcasts.apple.com/us/podcast/out-of-spec-podcast/id1576636119Spotify: https://open.spotify.com/show/0tKIQfKL9oaHc1DLOTWvbdAmazon: https://music.amazon.com/podcasts/473692b9-05b9-41f9-9b38-9f86fbdabee7/OUT-OF-SPEC-PODCASTFor further inquiries please email podcast@outofspecstudios.com Hosted on Acast. See acast.com/privacy for more information.

This week we interviewed Brennan Marilla. Brennan has a 30-year track record of driving growth and commercializing transformative therapies in med-tech. He currently serves as Chief Commercial & Operating Officer for Israeli start-up OSSIO, where he has helped build one of the fastest growing, disruptive companies in the orthopedic implant market over the last 6 years. Before OSSIO, he was Chief Commercial Officer for Surgical Specialties Corp (now Corza Medical), where significant improvements in top and bottom-line performance for the contract manufacturer led to a successful acquisition by Vivo Capital in 2017. Prior, he was VP & GM of Covidien's $650M Endovascular business and VP, Sales and Marketing for their $1B+ Peripheral Vascular sector. In his tenure, these franchises rapidly transformed into a market-leading brand through multiple product introductions, disruptive technology acquisitions, and market development campaigns.    Before Covidien, he spent 12 years at Medtronic where he was VP, US Sales and Director, Global Marketing for their aortic stent graft business, where he helped develop these therapies into what is now the standard of care in a $2 billion global market.

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: a new insulin pump gets FDA approval, once-weekly basal insulin for type 2 gets through another trial, New Jersey caps insulin prices for some, possible link between ability to chew and glucose control, a landmark diabetes study moves on to aging and T1D, JDRF Children's Congress and more! Learn about Moms' Night Out - a new event for moms of children with diabetes Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza  Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by AG1. AG1 helps you build your health, foundation first. XX Our top story, Tandem's Mobi Pump is approved. The FDA cleared the tiny pump for people with diabetes ages six and up. Tandem says mobie is fully controllable from a mobile app and is the world's smallest durable AID system. It still has a button on the pump to dose and holds 200 units. You use the same infusion set as the current Tandem pumps and Mobi uses Control IQ. Limited release planned for late this year and fully available early 2024. https://www.drugdeliverybusiness.com/fda-clears-tandem-mobi-automated-insulin-pump/ XX Learning more about a newly approved therapy for type 1 diabetes called Lantidra. Two safety and efficacy studies found that 21 participants who took Lantidra did not need to administer themselves insulin for a year or more. Twelve of those participants did not need to take insulin for up to 5 years, and 9 did not need insulin for over 5 years. Lantidra is an allogeneic (donor) pancreatic islet cellular therapy. In other words, Lantidra uses cells taken — or isolated — from human organ donor pancreases. “In [a] subsequent process, the insulin-producing islets are purified from the rest of the pancreatic tissue using a density gradient. Once the islets are isolated, purified, and put for a short time in cell culture, the cell preparation is infused into the liver of the recipient,” he explained. https://www.medicalnewstoday.com/articles/fda-approves-first-cellular-therapy-for-type-1-diabetes-what-does-it-do#How-does-islet-cellular-therapy-work? XX Once weekly basal insulin for type 2 gets through another trial. After 26 weeks of treatment and five weeks of follow-up, patients on weekly insulin icodec had significantly larger improvements in their HbA1C than those using daily insulin. Both groups had an extremely low rate of adverse events. These researches say next step is FDA evaluation. https://www.utsouthwestern.edu/newsroom/articles/year-2023/july-weekly-insulin-found-safe.html XX That's the idea behind Fractyl Health's treatment for type 2 diabetes—which could also be used for weight control. The Lexington, Massachusetts-based biotech company is in the early stages of developing a one-time gene therapy intended to lower blood sugar and body weight using the same mechanism as semaglutide. “You have this problem where you need to stay on therapy for efficacy,” says Harith Rajagopalan, a cardiologist by training and CEO and cofounder of Fractyl Health. “That's the Achilles heel.” The company wants to deliver an artificial gene to the pancreas that continuously produces the GLP-1 hormone so there's no need for weekly injections. The approach, called gene therapy, uses inactivated viruses to carry a therapeutic gene to pancreatic cells. (Viruses are used because of their natural ability to deliver genetic material to cells.) The company is aiming to begin an initial human trial by the end of 2024 https://www.wired.com/story/a-one-time-shot-for-type-2-diabetes-a-biotech-company-is-on-it/ XX Gov. Phil Murphy signed three bills into law Monday aimed at cutting the high cost of prescription drugs in New Jersey. The new laws will cap how much residents will pay for some popular medications such as insulin, prevent pharmacy benefit managers from engaging in practices that make drugs more expensive, and create a panel that will monitor prices set by pharmaceutical companies. One measure (S1614) would cap the cost of insulin, epinephrine auto-injector devices and asthma inhalers for state and local public workers enrolled in the State Health Benefits Program, the School Employees' Health Benefits Program and other state-regulated plans. For a 30-day supply, insulin will cost $35, EpiPens $25 and asthma inhalers would be capped at $50, according to the bill. The law takes effect next year. https://www.nj.com/politics/2023/07/new-laws-to-stem-high-cost-of-prescription-drugs-in-nj-were-just-signed-by-gov-murphy.html XX The European Medicines Agency (EMA) said on Tuesday it has extended its probe into Novo Nordisk's (NOVOb.CO) diabetes drugs Ozempic and weight-loss treatment Saxenda, following two reports of suicidal thoughts, to include other drugs in the same class. The agency began its review on July 3 after Iceland's health regulator flagged the reports of patients thinking about suicide and one case of thoughts of self harm after use of Novo's drugs. https://www.reuters.com/business/healthcare-pharmaceuticals/eu-extends-ozempic-probe-include-other-drugs-2023-07-11/ XX We often hear that diabetes can lead to problems with your teeth.. but one researcher says it might be the other way around. A University at Buffalo researchers says there is a notable correlation between chewing functionality and blood glucose levels in people with type 2. Specifically, he found that patients with T2D who maintain a full chewing ability exhibit significantly lower blood glucose levels compared to those with compromised chewing function. The thinking here is that chewing stimulates the body in all sorts of ways, including releasing hormones that help you feel fuller and help in digestion. More studies are expected. DOI: 10.1371/journal.pone.0284319 https://scitechdaily.com/the-surprising-connection-between-chewing-and-type-2-diabetes/ XX The next step of the landmark Diabetes Control and Complications Trial will focus on aging with type 1 diabetes. The original randomized DCCT clinical trial results, published September 30, 1993, in the New England Journal of Medicine, proved that early intensive glycemic control was the key to preventing or slowing the progression of long-term eye, kidney, and nerve complications of type 1 diabetes. Subsequently, EDIC has yielded many more major findings including that early tight glycemic control also reduces cardiovascular risk and prolongs survival in type 1 diabetes. subsequent EDIC data also have suggested that it is never too late to initiate intensive glycemic control Together, DCCT and EDIC — both funded by the National Institutes of Health at 27 sites in the United States and Canada — have changed the standard of care for people with type 1 diabetes Prior to the DCCT, between 1930 and 1970, about a third of people with type 1 diabetes developed vision loss and one in five experienced kidney failure and/or myocardial infarction. Stroke and amputation were also common, DCCT/EDIC chair David M. Nathan, MD, said while introducing the symposium. "All of the advances in care of type 1 diabetes have developed because this study demonstrated that it was important — continuous glucose monitoring (CGM), new insulins, better [insulin] pumps…I think the most profound finding is that mortality in our intensively treated cohort is the same as in the general population. That says it all," Nathan told Medscape Medical News. https://www.medscape.com/viewarticle/994221 XX Commercial – AG1 XX Today, JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, urged members of the Senate Appropriations Committee to renew the Special Diabetes Program (SDP) and support policies to ensure insulin is available at an affordable and predictable price. Opened by U.S. Senator Patty Murray (D-WA) and led by U.S. Senators Susan Collins (R-ME) and Jeanne Shaheen (D-NH), the hearing took place during the 2023 JDRF Children's Congress, a biennial event that brings over 160 kids and teens living with T1D face-to-face with lawmakers and top decision-makers. The youth delegates traveled to Washington, D.C. from across the country and JDRF's international affiliates in the United Kingdom, Australia, the Netherlands, and Canada. The SDP has accelerated the pace of T1D research through a long-term investment of funding at the National Institutes of Health. The program has led to significant scientific breakthroughs, including Tzield, the first disease-modifying treatment for T1D, which can delay the onset of the disease by over two years. Without Congressional action, the SDP will expire at the end of September. "The Special Diabetes Program has fundamentally changed what it means to live with diabetes, put new life-changing therapies in our hands, and brought us closer to cures," said Aaron Kowalski, Ph.D., JDRF CEO. "We must keep this momentum going so we can capitalize on the progress to date and realize cures. However, until we have cures, people need access to affordable insulin. JDRF urges Congress to pass the bipartisan INSULIN Act of 2023, which will establish a $35 per month insulin copay cap for people with commercial insurance and includes other provisions that would make insulin more affordable for everyone, regardless of insurance status." Dr. Kowalski was joined at the hearing by Dr. Griffin Rodgers, Director of the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health, who provided testimony on the scientific value of the SDP, and Jimmy Jam, award-winning producer, songwriter, musician, member of the Rock & Roll Hall of Fame, and T1D parent. "My son Max, who is now in his twenties, was just two years old when he was first diagnosed with type 1 diabetes. Late nights working on music became late nights working on music and waking up my son to test and manage his blood sugar levels," said Jimmy Jam. "Type 1 diabetes should be one of those things we can all agree on. Diabetes doesn't care if you're a Democrat or a Republican. We can all agree that there should be research to improve the lives of those with diabetes. We can all agree that insulin should be affordable for all who need it." Two 2023 JDRF Children's Congress delegates shared their T1D experience with the committee: Maria Muayad: 10-year-old Maria is from Maine and is a member of her school's civil rights club and math challenge group. Every November, Maria, and her mother, Golsin, give blue ribbons to the staff at her school in honor of National Diabetes Awareness Month. Elise Cataldo: 15-year-old Elise lives in New Hampshire and is passionate about educating those around her about life with T1D and tries to use things like pump site changes and blood sugar checks as opportunities to help others learn. Following the hearing, the 2023 JDRF Children's Congress delegates continued their advocacy by meeting with lawmakers in their Capitol Hill offices. https://www.prnewswire.com/news-releases/2023-jdrf-childrens-congress-delegates-urge-lawmakers-to-support-type-1-diabetes-research-and-access-to-affordable-insulin-301874927.htmlXX XX A 23-year-old with type 1 diabetes has broken the record for circumnavigating Britain in a kayak after paddling 2,000 miles in 40 days. Dougal Glaisher beat the previous record by 27 days. Glaisher was diagnosed with type 1 diabetes at the age of 19 shortly after winning the Oban Sea Kayak race in Scotland, when he had blurred vision and struggled to recover his energy. The expedition was to raise money for the UK-based charity Action4Diabetes and Glaisher livestreamed his blood sugar On Tuesday he was well stocked with a bunch of bananas and a stash of cereal bars lashed to his boat. But in remote areas it was more challenging. Around the islands off Scotland he ran out of freeze-dried meals and survived on porridge for several days. He also sourced drinking water from streams. . It is the first time anyone has used a surfski – a kayak that you sit on top of – to paddle around the country. XX On the podcast next week.. I sat down with Dexcom's new Chief Commercial officer to talk about their announcements from this week about the type 2 market and other features important to people with type 1. Our last epoisde is all about Kickass Healthy LADA That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: FDA approval for a pancreatic islet cell therapy to treat type 1, stem cell research moves ahead, big news from the ADA Scientific Sessions about what's next for medications like Mounjaro and a pill form of semaglutide. Dexcom announces a sensor for people with type 2 who don't use insulin, Libre moves ahead with Ketone monitoring and more.   Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza  Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by the T1D Exchange a nonprofit organization dedicated to improving outcomes for the entire T1D population. XX Big week of news following the 2023 ADA Scientific Sessions conference. What follows is just the tip of the information iceberg, so please follow the links in the show notes to much more. -- XX Top story though isn't from ADA – but a new FDA approval.. for a pancreatic islet cell therapy to treat type 1. It's called donislecel, developed from cadaver donors and giving as a single infusion straight into the liver. Immunosuppression is required to maintain cell viability, just as it is required to support a transplanted kidney or other organ. Approval was based on what seems to be a very small study – 30 people with type 1 who had hypoglycemic unawareness and who received between one and three infusions of donislecel. After one year, 11 people did not need to dose insulin.. 10 stayed that way for more than five years. But five people in the study were not able to stop dosing insulin at all. This method is different from what Vertex and Sernova are trying to do with stem cell therapy. https://www.medscape.com/viewarticle/993854 XX Vertex moves forward on their clinical trial of islet stem cell therapy. All six patients treated with VX-880 had undetectable fasting C-peptide (endogenous insulin secretion) at baseline, a history of recurrent SHEs in the year prior to treatment and required an average of 34.0 units of insulin per day. Following treatment, all six patients demonstrated endogenous insulin secretion, improved glycemic control as measured by HbA1c, improved time-in-range on continuous glucose monitoring, and reduction or elimination of exogenous insulin use. Two patient are completely insulin independent after one year – with an A1C of 5.3 compard to 8.6 at baseline.. the other 6.0 with a 7.6 at baseline – again the ”after” number is without taking insulin. As a result of these safety and efficacy data in Parts A and B, the independent data review committee has recommended moving to Part C of the trial, which allows for concurrent dosing of patients at the full target dose of VX-880. https://www.businesswire.com/news/home/20230623446641/en/Vertex-Presents-Positive-VX-880-Results-From-Ongoing-Phase-12-Study-in-Type-1-Diabetes-at-the-American-Diabetes-Association-83rd-Scientific-Sessions XX Sernova also reports good results with their cell pouch system. Five of the six patients who have completed implantation continue to experience insulin independence for periods ranging from six months to more than three years. The sixth patient only recently completed the protocol-defined islet transplants.. so no results yet. There is a second group testing a larger cell pouch. https://www.drugdeliverybusiness.com/sernova-interim-data-cell-pouch-system/ XX Big news from ADA about all of the type 2 and obesity drugs you've likely heard about.. here are some headlines: SURMOUNT-2 clinical trial evaluating tirzepatide – brand name Mounjaro - for weight loss in adults with obesity or overweight and type 2 diabetes. Average weight loss was 15.7% at the highest dose, with many other health benefits such as lower A1C levels; reduction in waist circumference, and body mass index; and improvements in cardiometabolic disease risk factors such as lipid levels, cholesterol, and blood pressure. That 15 percent weight loss was about 34 pounds and the a1c reduction for half of those in the study went down to 5.7 which is considered nondiabetic. Mounjaro is currently approved for type 2 and the FDA could approve Mounjaro regardless of diabetes status later this year. https://diatribe.org/new-lilly-trial-results-show-big-weight-loss-results-positioning-mounjaro-obesity-drug-approval XX A study called PIONEER looks at oral semaglutides – some calling it the Ozempic pill. When compared to other anti-diabetic medications such as Jardiance, Januvia and Victoza, people taking the oral semaglutide say 1% or or more reduction of HbA1c compared to those treated with other anti-diabetic medicines. They also were more like to achieve a 5% or more reduction of body weight. Note: this was not a study comparing a semaglutide pill with the same type of injection. https://www.news-medical.net/news/20230607/Oral-semaglutide-outperforms-other-medications-in-type-2-diabetes-treatment-significantly-reducing-HbA1c-and-body-weight.aspx XX And look for two additional new drugs to treat obesity in the next few years.. orforglipron, is easier to use and to produce, and it will probably be cheaper than existing treatments. The second, retatrutide, has an unprecedented level of efficacy, and could raise the bar for pharmacological obesity treatment. Orforglipron and retatrutide both mimic hormones produced by the lining of the gut in response to certain nutrients. These hormones help to slow the passage of food through the digestive tract and lower appetite by acting on receptors in the brain — both effects that reduce people's desire to eat and help them to lose weight. Orfoglipron is a non-peptide molecule that researchers say is easy to produce and is a pill.. a lower price is anticipated for this one. Retratritude looks like it could help people lose even more weight than Mounjaro. https://www.nature.com/articles/d41586-023-02092-9 XX Dexcom announces a new product in the US – coming in 2024 – designed for people with type 2 who don't use insulin. This will be built on the G7 hardware, but with different software and a 15 day sensor. CEO Kevin Sayer also announced that the G7 will be able to share data direct to the apple watch https://www.businesswire.com/news/home/20230623025076/en/Global-Continuous-Glucose-Monitoring-Pioneer-Dexcom-Reveals-New-Plans-to-Bring-Sensing-Technology-to-Millions-More XX Abbott will partner with Weight Watchers - people who have been prescribed one of Abbott's FreeStyle Libre 14-Day or FreeStyle Libre 2 sensors and who are using the WeightWatchers diet plan to see their CGM data directly in the WeightWatchers app. This is also a study where Abbott will launch two pilot programs directed at using CGM data to help people with Type 2 diabetes adjust and manage their dietary habits, regardless of whether they're on insulin therapy. XX A little bit more news about Abbott's dual glucose and ketone sensor under development. Announced a last year's ADA, the company says it's moving forward through R&D Separately from the Type 2 CGM push, Taub also offered an update on the dual glucose ketone sensor that's currently under development at Abbott and that the company first announced at last year's ADA conference. The sensor will be aimed at catching rising ketone levels as early as possible to help avoid cases of diabetic ketoacidosis. An Abbot executive says – quote - “There's so much that we stand to learn about ketones because there hasn't been a continuous sensor for them before, so there's really very little we know about the evolution of ketones “ https://www.fiercebiotech.com/medtech/ada-abbott-pushes-widespread-cgm-use-type-2-diabetes-weightwatchers-ada-collabs XX Commercial XX Beta Bionics has received FDA 510(k) clearance for the compatibility of the Fiasp Pumpcart prefilled insulin cartridge with the iLet automated insulin-delivery system. The iLet is a bionic pancreas that fully automates 100% of all user insulin doses, providing users with the choice of three insulins, Novolog; Humalog; and Fiasp Pumpcart. The device eases diabetes management in everyday life and almost eliminates the expertise that has been required in the past to set up and manage a traditional insulin pump. In May 2023, Beta Bionics was awarded FDA approval for the iLet device. The iLet manages glucose levels with just a meal announcement and is paired with a Dexcom G6 Continuous Glucose Monitoring System for glucose readings. All that is required for set-up is the user's weight. While there is a need for carbohydrate awareness, no carb counting is necessary. Bolusing, correction factors, insulin-to-carb ratios, and pre-set basal rates are also unnecessary. Beta Bionics president and CEO Sean Saint said: “Beta Bionics has been working tirelessly to create an insulin delivery system that offers less burden and more convenience for the type 1 community. Since launching last month, the iLet bionic pancreas is now available and clinics and users are being trained on its simple design and easy management features. “When Fiasp Pumpcart prefilled cartridges are available, users will save time not having to manually fill cartridges and will have more choice for their diabetes management.” https://www.medicaldevice-network.com/news/beta-bionics-gains-fda-clearance-for-prefilled-insulin-cartridge/ XX Oura – the ring that tracks your sleep – will start sending info to three CGM info companies.. January, Supersapiens and Veri. All three of these companies provide software based off of the Libre CGM. These companies will now be receiving sleep scores and other biometric data from Oura so they can see how these measurements affect users' glucose levels and overall health. https://www.forbes.com/sites/andrewwilliams/2023/06/27/oura-smart-ring-can-be-used-to-help-monitor-blood-sugar/?sh=2520116c2b10 XX Just a fun fact here – there is a Facebook group called type 1 diabetics for 50 plus years. And it looks like this week they passed over 1500 members. XX On the podcast next week.. I sat down with Dexcom's new Chief Commercial officer to talk about their announcements from this week about the type 2 market and other features important to people with type 1. Our last epoisde is all about Kickass Healthy LADA That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Kate Moody, Customer Strategy Director at 11:FS is joined by some great guests to talk about the most notable fintech, financial services and banking news from the past week. This week's guests include: Sophie Guibaud, Co-Founder and Chief Commercial & Growth Officer, Fiat Republic and Co Author of the Embedded Finance Book: When Payments Become An Experienc Hussein Fazal, CEO, Super.com Tui Allen, VP of Product at Ampla We cover the following stories from the fintech and financial services space: Super.com raises $85m for savings super app Could First Republic be the next SVB? - Shopify launches eCommerce payments tool with help from Israeli fintech Melio More Banks Join European Instant Payments Pilot From End 2023 Klarna unveils AI-powered personalised shopping feed This episode is sponsored by Thredd Global Processing Services (GPS), the payments platform trusted by the leading issuers to process billions of transactions a year, has changed their name to Thredd. Why Thredd? Thredd, because their tailored payment processing solutions are the thread that connects payments innovators of the future. Thredd, because they are true partners, becoming part of the fabric of your business as it grows. And Thredd because it just feels right. Find out more at Thredd.com. (https://www.thredd.com/?utm_source=newsletter&utm_medium=email&utm_campaign=bitesize+thredd&utm_id=11fs) Fintech Insider by 11:FS is a podcast dedicated to all things fintech, banking, technology and financial services. It's hosted by a rotation of 11:FS experts including David M. Brear, Ross Gallagher, Benjamin Ensor, and Kate Moody - as well as a range of brilliant guests. We cover the latest global news, bring you interviews from industry experts or take a deep dive into subject matters such as APIs, AI or digital banking. If you enjoyed this episode, don't forget to subscribe and please leave a review Send us your questions for the Fintech Insider Mailbag here (https://11fscompany.typeform.com/to/kBMan5qL?typeform-source=t.co) Follow us on Twitter: @fintechinsiders where you can ask the hosts questions, or email podcasts@11fs.com! Special Guests: Hussein Fazal, Sophie Guibaud, and Tui Allen.

Our expert host, David Barton-Grimley, is joined by some great guests to ask: "“How does embedded finance make money?” This week's guests include: Tui Allen, Vice President of Product, Ampla Sophie Guibaud, Co-Founder and Chief Commercial & Growth Officer, Fiat Republic Nadya Hijazi, Global Head of Wholesale Digital Channels, HSBC Embedded finance has the ability to bring financial inclusion to those previously excluded and provide genuinely helpful services at the point of need. But, revenue is important to making sure that embedded finance is a sustainable option. In this week's show we're looking at how you set up an embedded finance partnership, how to make it successful, and how do you make it profitable. Fintech Insider by 11:FS is a podcast dedicated to all things fintech, banking, technology and financial services. It's hosted by a rotation of 11:FS experts including David M. Brear, Ross Gallagher, Benjamin Ensor, and Kate Moody - as well as a range of brilliant guests. We cover the latest global news, bring you interviews from industry experts or take a deep dive into subject matters such as APIs, AI or digital banking. If you enjoyed this episode, don't forget to subscribe and please leave a review Send us your questions for the Fintech Insider Mailbag here (https://11fscompany.typeform.com/to/kBMan5qL?typeform-source=t.co) Follow us on Twitter: @fintechinsiders where you can ask the hosts questions, or email podcasts@11fs.com! Special Guests: Nadya Hijazi, Sophie Guibaud, and Tui Allen.

Gary Long is the Chief Executive Officer of Botanical Sciences. With an extensive background in healthcare in the state and across the country, Long is uniquely qualified to lead Botanical Sciences on its journey to provide hope and relief for the patients of Georgia. Most recently, Long served as Executive Vice President and Chief Commercial […] The post Gary Long With Botanical Sciences appeared first on Business RadioX ®.

Today on That Tech Pod, Laura and Gabi speak with Andrew Kelley. Andrew is a global technology executive with public company and startup experience. He is currently VP Corporate Development & Ventures at Five9. Prior to this role Andrew was Chief Commercial at an Internet of Things startup, BoxLock. As CEO of Bell Creek Partners he consulted for various private equity firms and early stage companies. Andrew is passionate about technology, customer scaling, and growth. Previously he was with Vista Equity-backed Omnitracs as President of Haulme and VP Corporate Development. He worked at Dell focusing on early stage investing in software and infrastructure startups including Nutanix which had a $2.5B market cap at IPO. He also worked at UBS Investment Bank in Technology, Media, & Telecom after working at IBM headquarters. He began his professional career co-founding Virtual Ink at MIT. Andrew has an MBA from Harvard Business School, an MSME from MIT, and a BSME from North Carolina State University.

This week on Great Minds, we're pleased to welcome Kevin Gentzel. Kevin is the Global Chief Commercial and Growth Officer of Newsweek. He previously worked at Gannett | USA TODAY NETWORK as a President Marketing Solutions and CRO. Kevin Gentzel attended the University of Florida.

This week on Great Minds, we're pleased to welcome Kevin Gentzel. Kevin is the Global Chief Commercial and Growth Officer of Newsweek. He previously worked at Gannett | USA TODAY NETWORK as a President Marketing Solutions and CRO. Kevin Gentzel attended the University of Florida.

Geoff Tanner is a passionate believer in the power of breakthrough creative. That philosophy and his passion for music lead to some of the most iconic campaigns of the past 10 years. Geoff oversees the consumer and customer experience across the commercial funnel. He has a unique perspective on the blending of sales and marketing that helped JM Smucker transform from having a “sleepy” brand portfolio to being named on Fast Company‘s list of the World's Most Innovative Companies.  In this episode, Alan and Geoff discuss the key elements JM Smucker targeted to transform the brand portfolio, marketing strategy, and operating model. Geoff tells us what  “The Power of One” is, the importance of household penetration and reach, and how improved metrics will impact the future of marketing and creative   In this episode, you'll learn:  How diverse the JM Smucker portfolio is and the impact of multiple acquisition  How to maintain relevance for a brand that is over 100 years old Issues with ROI and impact measurements, and what the future may look like  Key Highlights  [01:30] How Geoff is giving back to his community through music [05:22] The path from rugby in New Zealand to the C Suit at JM Smucker [08:15] How the public should think about JM Smucker's portfolio [09:25] JM Smucker's transformation and new marketing model  [13:15] The key elements Geoff and his team had to change to reach their goals  [13:50] What is the “Power of One” and how did it impact their agency search [15:00] Identifying what was most critical to driving the business [16:10] Modernizing Meow Mix  [17:45] Ludacris and Jif Peanut Butter  [18:50] Facelift for Folgers  [20:20] The Byron Sharp and Mark Ritson Influence  [22:45] Transforming the “selling machine” [24:30] Markers of growth [27:05] The balance of reach and creative [28:25] Talk about JB Steenkamp [29:15] How getting an internship at Heinze shaped Geoff's perspective [31:25] Give back earlier and know your value [34:15] The fusion between sales and marketing  [35:50] Brands Geoff has his eye on [37:05] The threats and opportunities associated with mass media measurement Resources Mentioned:  Geoff Tanner  J.M. Smucker Co  Brand Portfolio – JIF, Folgers, Meow Mix, Milk-Bone, Smuckers, Uncrustables, and more  OpeningTrack.org – Opening Track Project and partnership with Girls & Boys Club of NE Ohio  Mark Smucker, CEO  Smucker consolidated marketing agency relationships in 2018 with further consolidation in 2021  Meow Mix Creative Examples  JIF Ludacris Creative  Folger's Joan Jett Creative   Mark Ritson on Marketing Today  Byron Sharp on Marketing Today  JB Steenkamp on Marketing Today  Brand mention: Oreo – Justin Parnell on Marketing Today   Follow the podcast:  Listen in iTunes (link: http://apple.co/2dbdAhV)  Listen in Google Podcasts (link: http://bit.ly/2Rc2kVa)  Listen in Spotify (Link: http://spoti.fi/2mCUGnC)   Connect with the Guest:  https://www.linkedin.com/in/geoff-tanner/  https://www.instagram.com/jmsmuckerco/   Connect with Marketing Today and Alan Hart:  Twitter Alan B Hart - http://twitter.com/abhart  LinkedIn Alan  - https://www.linkedin.com/in/alanhart  Twitter Marketing Today - http://twitter.com/themktgtoday  Facebook Marketing Today - https://www.facebook.com/themktgtoday/  LinkedIn Marketing Today - https://www.linkedin.com/company/marketing-today-with-alan-hart/  Support the show: https://www.patreon.com/marketingtodaySee omnystudio.com/listener for privacy information.

We've released over 200 podcasts through our usual InsTech channel. At InsTech, we're also keen listeners of other people's podcasts. During 2023, we will be sharing a selection of the podcasts that we like, or appear in, through an occasional mid-week or holiday season release. For this episode, we're bringing you the “Making Risk Flow Podcast” from Cytora. Cytora's Chief Commercial and Operations Officer, Juan de Castro, is talking to two insurance companies about the challenges that insurers and brokers are facing and how they've overcome those. Nic Brown, Divisional Director - Broker from Markel UK and James Wright, Head of Technology at Beazley Digital joined Juan in front of a live audience.  Topics include: How technology can add value to the broker The opportunities within the sector around data analysis  How Cytora helps companies to gain efficiency savings through automating processes You can learn more about Cytora and what we are doing with them from the company's dedicated page on the InsTech website. Cytora, Beazley and Markel are all InsTech corporate members. Contact us hello@instech.co to learn more about why over 170 companies around the world are working with InsTech. If you like what you're hearing, please leave us a review on whichever platform you use or contact Matthew Grant on LinkedIn. Sign up to the InsTech newsletter for a fresh view on the world every Wednesday morning. This podcast can be included as part of your CII CPD requirement should you consider it relevant to your professional development needs.

Today's episode discusses the increasing need for customer loyalty in the railway industry for the first time! Renfe is the leading train company in Spain, carrying over 500 million passengers a year and at 80 years old, they are facing new challenges as a business, with increasing competition not only from cars and flights as in the past, but also now from two new rail operators. Our interview is with Javier Marin Martinon, Chief Commercial, Loyalty, and Customer Officer, who shares some great ideas that Renfe has already launched for members of its loyalty program – designed to be simple and exciting to understand even when they are sometimes quite difficult behind the scenes to deliver! A great case study and an example of how to learn about loyalty from other industries to create compelling strategies for your own business needs. Show Notes: 1) Javier Marin Martinon, Chief Commercial, Loyalty, and Customer Officer 2) Renfe 3) Más Renfe

Trent discusses growing Jushi's footprint through M&A, leading the charge with retail and the future of cannabis.